Navigation Links
CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement
Date:2/28/2008

Seeks Exclusion Order Barring Importation of CryoCath's Cryoablation System

SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it has filed a formal complaint with the United States International Trade Commission (ITC) alleging that CryoCath Technologies Inc. has engaged in unfair trade practices by infringing on several CryoCor patents with its cryoablation system. CryoCor is requesting that the ITC initiate an investigation and issue an exclusion order to bar the importation into the United States of infringing CryoCath cryoablation products.

CryoCor's complaint covers three patents exclusively licensed to CryoCor in certain fields of use related to its Cardiac Cryoablation System, including patents covering pre-cooling technologies that CryoCor considers important to CryoCath's cryoablation system. This action is independent of a patent interference that has been declared by the United States Patent and Trademark Office between CryoCor and CryoCath, where CryoCor has been declared the senior party.

If the ITC accepts the complaint, it will institute a formal Section 337 investigation within 30 days. Section 337 investigations are completed on a fast track, typically within 15 months of the submission of the complaint. If the ITC determines that CryoCath's cryoablation system infringes on CryoCor's licensed patents and that CryoCath's products are being imported into the United States, the ITC may order that CryoCath's cryoablation system, and associated catheters and parts, be completely excluded from importation into the U.S. market for the life of the patents. ITC exclusion orders are enforced by the U.S. Customs and Border Protection.

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "Our request for this investigation further reinforces our strategy to protect our intellectual property r
'/>"/>

SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. United States Patent Office Grants CryoCors Request for Patent Interference
2. CryoCor Files Patent Infringement Lawsuits Against CryoCath
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. CryoCor to Present at CIBC World Markets 18th Annual Healthcare Conference
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. Sinovac Requests Extension for Annual Shareholders Meeting
7. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
8. International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy
9. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
10. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
11. IBF Conferences Inc., (International Business Forum) and BioEnterprise Present the 2nd Annual Global Healthcare Investing Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... 16 Exiqon today announces,the adoption of the ... the company,s commitment to expanding its business to ... guide treatment,decisions in oncology., Exiqon is pleased ... for their,clinical laboratory diagnostics business, Exiqon Diagnostics. This,progressive ...
... Oct. 16 Gaining a first-cycle,approval for a ... $640,million in incremental revenue on average, according to ... of PAREXEL International (Nasdaq: PRXL ),and leading ... device industries. According to the PAREXEL Consulting,analysis, 60 ...
... of carbon nanotubessorted by centrifuge for lengthmaterials scientists ... (NIST) have made some of the most precise ... mats of nanotubes become transparent, conducting sheets. Their ... relatively homogeneousnot overly short, but uniform in length ...
Cached Biology Technology:Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 2Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5Paperwork: Buckypapers clarify electrical, optical behavior of nanotubes 2
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... or simply cli-fi, is a newly coined term for novels ... New research from University of Copenhagen shows how these fictions ... the potential consequences of climate change and imagine other living ... data on changes in the atmosphere; it is also a ... books we read and the films we see. And there ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... (May 23, 2008) A study led by Gregg ... Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, ... the direct thrombin inhibitor bivalirudin during primary angioplasty had ... rate of major bleeding, and a lower mortality rate ...
... May 22, Shire plc (LSE: SHP)(NASDAQ: SHPGY ... High Court approved,the scheme of arrangement between Shire ... The scheme, which becomes effective on 23 May ... Limited (LSE: SHP,NASDAQ: SHPGY) becoming the new holding ...
... international team of scientists surveying the waters of the ... has discovered for the first time high levels of ... raising concern for marine ecosystems from Canada to Mexico. ... research vessel, also discovered that this corrosive, acidified water ...
Cached Biology News:Findings released from 1 of the largest percutaneous coronary intervention trials ever 2Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3
... When Ambion introduced the highly potent TURBO DNase ... new standard was set in DNA removal capabilities. ... DNase I that is much more efficient than ... amounts of unwanted DNA. TURBO DNase binds DNA ...
...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: